Max Healthcare Institute Ltd (MAXHEALTH) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported its 20th consecutive quarter of consistent growth, demonstrating strong momentum across its network.
- Overall performance was driven by the strength of core operations, with existing units showing robust revenue and EBITDA growth of 14% and 19% respectively, indicating healthy underlying business performance.
- The company is aggressively pursuing capacity expansion through several brownfield projects, with new towers at Nanavati Max and Max Smart set to be commissioned imminently, adding over 650 beds to the network.
- International patient revenue continued its strong growth trajectory, increasing by 25% year-on-year, primarily driven by higher patient volumes from key geographies like the Middle East, Eastern Europe, and Africa.
- The company successfully resolved an impasse with certain insurance players regarding cashless facilities and anticipates a significant positive financial impact of over 200 crores from the recent revision in CGHS prices once fully implemented.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.